Kedudukan dalam Saham
#27149
Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in... Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.
Harga Saham
$3.17
Disegerakkan terakhir: 2021-08-31
Perubahan (1 hari)
-7.31%
Perubahan (1 tahun)
0.00%
Perdagangan Cytocom, Inc. (CBLI)
Pendapatan untuk Cytocom, Inc. (CBLI)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Cytocom, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Cytocom, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun |
Pendapatan |
Ubah |
|
Tidak cukup data untuk tarikh yang disediakan. |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat |
Pendapatan |
Perbezaan Pendapatan |
Negara |
|
|
$5.27B |
-
|
US
|
|
|
$-3.09B |
-
|
US
|
|
|
$1.95B |
-
|
NL
|
|
|
$1.61B |
-
|
AU
|
|
|
- |
-
|
CH
|